IPP Bureau
BD, Suttons Creek partner to streamline combination product development
By IPP Bureau - April 30, 2026
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
By IPP Bureau - April 30, 2026
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push
By IPP Bureau - April 30, 2026
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
By IPP Bureau - April 30, 2026
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Sahajanand Medical Technologies secures ISO 50001:2018 certification for Surat, Hyderabad facilities
By IPP Bureau - April 30, 2026
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Solara announces closure of US FDA inspection at Puducherry facility
By IPP Bureau - April 30, 2026
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Wanbury's Patalganga site clears Korea FDA inspection with zero observations
By IPP Bureau - April 30, 2026
Patalganga plant received zero observation from USFDA earlier
KIMS enters into MoU for strategic clinical collaboration
By IPP Bureau - April 30, 2026
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
Pfizer drug delivers breakthrough in late-stage blood cancer trial
By IPP Bureau - April 30, 2026
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
By IPP Bureau - April 30, 2026
The agreement could rise to $900 million if key commercial milestones are met
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
By IPP Bureau - April 30, 2026
The Danish biotech company confirmed the global study will begin in the second half of 2026
Gen Z split on AI as global study reveals rising tech optimism
By IPP Bureau - April 30, 2026
Health innovations are viewed more positively than food and agricultural technologies
CPHI & PMEC India 2026 expand to dual venues in Delhi NCR
By IPP Bureau - April 30, 2026
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Monitra Health raises fresh funding to scale upBeat® cardiac monitoring platform globally
By IPP Bureau - April 30, 2026
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action
By IPP Bureau - April 30, 2026
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
